Sign up to save your podcasts
Or
Share Healthier World with Quest Diagnostics
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Healthier World with Quest Diagnostics
Healthier World with Quest Diagnostics episodes
- 07 - Action from insight: Tackling insulin resistance (18 min)
Identifying insulin resistance offers significant—and often untapped—clinical value and can help healthcare providers and their patients take action with diet and lifestyle choices to avoid or change the progression to prediabetes and diabetes. Today’s episode features Patty Bianchi, Registered Dietitian Nutritionist and Certified Diabetes Care and Education Specialist and Trisha Winchester, PhD, Quest Diagnostics Sr Manager for Clinical & Education.
This episode will
- Review glucose regulation by insulin (1:15)
- Discuss how insulin resistance is measured (3:00)
- Review actionable ways to reduce insulin resistance through lifestyle (4:00), exercise (6:30), diet (8:50), stress and sleep (11:50)
- Discuss the 4myheart patient education program offered through Quest Diagnostics Center of Excellence at Cleveland Heartlab (14:30)
The content was current as of the time of recording. To learn more, please review the additional resources below for information on our cardiovascular, metabolic, endocrine, and wellness offerings as well as educational resources and insights from our team of experts. At Quest Diagnostics, we are committed to providing you with results and insights to support your clinical decisions.
Date: 11/2024
Speaker(s): Patty Bianchi, RDN, CDCES; Trisha Winchester, PhD
Contributor(s): Trisha Winchester, PhD; Patty Bianchi, RDN, CDCES; Maeson Latsko, PhD
Additional Resources:
Podcast: The Insulin Resistance Revolution: The Key to Preventing Chronic Conditions (17 min)
Webinar: Early Identification of Type 2 Diabetes Risk for the Primary Care Setting
Ordering information:
Insulin Resistance Panel with Score | Test Detail | Quest Diagnostics
Insulin Resistance Panel with Score | Test Summary | Quest Diagnostics
19 min - 06 - The insulin resistance revolution: The key to preventing chronic conditions (17 min)
Metabolic dysfunction is a common root cause of many cardiometabolic conditions that burden the healthcare system. This episode will address insulin resistance, a syndrome that underlies metabolic dysfunction, and how tools can catch risk early, allowing actions that may prevent and reverse the onset of chronic illness. Today’s episode is with Quest Diagnostics experts Kenneth French, Senior Clinical Consultant, and Dr Maeson Latsko, clinical and education specialist.
This episode will
- Identify how early identification of insulin resistance can prevent the rise in metabolic dysfunction and Type II Diabetes (3:00)
- Describe the insulin resistance panel with score (8:11)
- Elucidate how identifying insulin resistance can prevent other chronic illness, such as liver related disorders and kidney disease (12:41)
The content was current as of the time of recording. To learn more, please review the additional resources below for information on our cardiovascular, metabolic, endocrine, and wellness offerings as well as educational resources and insights from our team of experts. At Quest Diagnostics, we are committed to providing you with results and insights to support your clinical decisions.
Date: 09/2024
Speaker(s): Kenneth French; Maeson Latsko, PhD
Contributor(s): Maeson Latsko, PhD; Trisha Winchester, PhD; Kenneth French
Additional Resources:
Podcast: Action from Insight: Tackling Insulin Resistance (18 min)
Webinar: Early Identification of Type 2 Diabetes Risk for the Primary Care Setting
Ordering information:
Insulin Resistance Panel with Score | Test Detail | Quest Diagnostics
Insulin Resistance Panel with Score | Test Summary | Quest Diagnostics
References:
- Ward ZJ, Bleich SN, Cradock AL, et al. Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity. N Engl J Med. 2019;381(25):2440-2450. doi:10.1056/NEJMsa1909301
- Abbasi F, Shiffman D, Tong CH, et al. Insulin resistance probability scores for apparently healthy individuals. J Endocr Soc. 2018;2(9):1050-1057. doi:10.1210/js.2018-00107
- Bril F, McPhaul MJ, Kalavalapalli S, et al. Intact fasting insulin identifies nonalcoholic fatty liver disease in patients without diabetes. J Clin Endocrinol Metab. 2021;106(11):e4360-e4371. doi:10.1210/clinem/dgab417
- Healy, M. By 2030, nearly half of all U.S. adults will be obese, experts predict. New York Times. https://www.latimes.com/science/story/2019-12-18/nearly-half-of-us-adults-will-be-obese-by-2030
- Khan RMM, Chua ZJY, Tan JC, et al. From Pre-Diabetes to Diabetes: Diagnosis, Treatments and Translational Research. Medicina (Kaunas). 2019;55(9):546. doi:10.3390/medicina55090546
18 min - 05 - Instant insights: Apolipoprotein B (7 min)
Despite advances in understanding the pathogenesis and prevention of atherosclerotic cardiovascular disease, coronary heart disease remains the leading cause of death in the United States. Apolipoprotein B (ApoB)—containing lipoproteins more closely identifies atherosclerosis and correlates to atherogenic particles in circulation.
This episode will:
- Review the current state of cardiovascular risk assessment
- Describe lipoprotein anatomy and ApoB
- Identify discordance between LDL cholesterol and ApoB
- Discuss the guideline recommended clinical utility of ApoB in risk identification
The content was current as of the time of recording. To learn more, please review the additional resources below for information on our cardiovascular, metabolic, endocrine, and wellness offerings as well as educational resources and insights from our team of experts. At Quest Diagnostics, we are committed to providing you with results and insights to support your clinical decisions.
Date: 9/10/24
Speaker(s): Maeson Latsko, PhD
Contributor(s): Maeson Latsko, PhD; Trisha Winchester, PhD
Additional Resources:
Quest Diagnostics Clinical Education Center [Link]
Ordering information: Apolipoprotein B | Test Detail | Quest Diagnostics
Apolipoprotein B | Test Summary | Quest Diagnostics
Apo B and cardiovascular risk | Quest Diagnostics | Quest Diagnostics
References:
Sniderman AD, Williams K, Contois JH, et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein b as markers of cardiovascular risk. Circ: Cardiovascular Quality and Outcomes. 2011;4(3):337-345. doi:10.1161/CIRCOUTCOMES.110.959247
Johannesen CDL, Langsted A, Nordestgaard BG, Mortensen MB. Excess apolipoprotein B and cardiovascular risk in women and men. J Am Coll Cardiol. 2024;83(23):2262-2273. doi:10.1016/j.jacc.2024.03.423
Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e1143. doi:10.1161/CIR.0000000000000625
Contois JH, McConnell JP, Sethi AA, et al. Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clin Chem. 2009;55(3):407-419. doi:10.1373/clinchem.2008.118356
8 min - 04 - Instant insights: Lipoprotein (a) (6 min)
Despite advances in understanding the pathogenesis and prevention of atherosclerotic cardiovascular disease, coronary heart disease remains the leading cause of death in the United States. Lipoprotein (a), or Lp(a), is a particularly atherogenic type of lipoprotein, where excess levels significantly influence cardiovascular risk.
This episode will:
- Review the significant cardiovascular implications of Lp(a) excess
- Describe Lp(a) structure
- Discuss how Lp(a) is measured
- Review the treatment landscape for Lp(a)
The content was current as of the time of recording. To learn more, please review the additional resources below for information on our cardiovascular, metabolic, endocrine, and wellness offerings as well as educational resources and insights from our team of experts. At Quest Diagnostics, we are committed to providing you with results and insights to support your clinical decisions.
Date: 9/10/24
Speaker(s): Maeson Latsko, PhD
Contributor(s): Maeson Latsko, PhD; Trisha Winchester, PhD
Additional Resources:
Ordering information: Lipoprotein (a) | Test Detail | Quest Diagnostics
Lipoprotein(a) | Test Summary | Quest Diagnostics
Quest Diagnostics Clinical Education Center [Link]
References:
Wilson DP, Jacobson TA, Jones PH, et al. Use of Lipoprotein(A) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. J Clin Lipidol. 2019;13(3):374-392. doi:10.1016/j.jacl.2019.04.010
Koschinsky ML, Bajaj A, Boffa MB, et al. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. J Clin Lipidol. 2024;18(3):e308-e319. doi:10.1016/j.jacl.2024.03.001
6 min - 03 - Laboratory assessment in the diagnosis of male Hypogonadism (16 min)
Hypogonadism is a common condition in the male population, impacting approximately 35% of men over 45 years of age. Today’s episode is with Quest Diagnostics experts Dr Sanjay Dixit, MD, medical director, and Maeson Latsko, PhD, clinical specialist.
This episode will:
- Review the clinical and biochemical changes seen in male patients with hypogonadism (1:20)
- Discuss the guideline-recommended methodologies for testosterone analysis (3:24)
- Learn how to delineate between primary and secondary hypogonadism (7:38)
The content was current as of the time of recording. To learn more, please review the additional resources below for information on our cardiovascular, metabolic, endocrine, and wellness offerings as well as educational resources and insights from our team of experts. At Quest Diagnostics, we are committed to providing you with results and insights to support your clinical decisions.
Date: May 3, 2024
Contributor(s): Dr. Sanjay Dixit, MD, Maeson Latsko, PhD
Additional Resources:
Quest Diagnostics Clinical Education Center
Quest Diagnostics Hypogonadism FAQs
Clinical Focus: Hypogonadism and Low Testosterone in Men
Adult Male Hypogonadism Diagnostic Algorithm
References See Quest Diagnostics Clinical Education Center
17 min - 02 - Laboratory testing for the diagnosis and management of thyroid disorders (21 min)
An estimated 20 million Americans have some form of thyroid disease, and up to 60% of them are unaware of their condition. Today’s episode is with Quest Diagnostics experts Dr Sanjay Dixit, MD, medical director, and Sarah Walsh, PA-C, CLS, clinical specialist.
This episode will:
- Identify common signs and symptoms of thyroid dysfunction
- Identify lab recommendations to support the diagnosis of hypo- and hyperthyroidism
- Discuss the association between cardiometabolic conditions and thyroid dysfunction
The content was current as of the time of recording. To learn more, please review the additional resources below for information on our cardiovascular, metabolic, endocrine, and wellness offerings as well as educational resources and insights from our team of experts. At Quest Diagnostics, we are committed to providing you with results and insights to support your clinical decisions.
Date: 4/18/2024
Speaker(s): Dr. Sanjay Dixit, MD; Sarah Walsh, PA-C, CLS
Contributor(s): Sarah Walsh, PA-C, CLS; Dr. Sanjay Dixit, MD; Trisha Winchester, PhD; Maeson Latsko, PhD
Additional Resources:
Quest Diagnostics Clinical Education Center
Quest Diagnostics Thyroid Disorders
Clinical Focus: Thyroid Dysfunction in Nonpregnant Adults
Testing Algorithm for Thyroid Dysfunction in Nonpregnant Adults
References See Quest Diagnostics Clinical Education Center
21 min - 01 - Laboratory assessment in PCOS diagnosis and management (19 min)
Polycystic Ovary Syndrome (PCOS) is one of the most common endocrine diagnoses for reproductive-aged women and carries lifelong cardiometabolic risk. Today’s episode is with Quest Diagnostics experts Dr Sanjay Dixit, MD, medical director, and Sarah Walsh, PA-C, CLS, clinical specialist.
This episode will:
- Review the diagnostic criteria for PCOS (2:00)
- Identify lab recommendations to support the diagnosis of PCOS (6:00)
- Discuss associated cardiometabolic conditions and how to screen and monitor for these conditions (14:45)
The content was current as of the time of recording. To learn more, please review the additional resources below for information on our cardiovascular, metabolic, endocrine, and wellness offerings as well as educational resources and insights from our team of experts. At Quest Diagnostics, we are committed to providing you with results and insights to support your clinical decisions.
Date recorded: 4/9/2024
Speaker(s): Dr. Sanjay Dixit, MD; Sarah Walsh, PA-C, CLS
Contributor(s): Sarah Walsh, PA-C, CLS; Dr. Sanjay Dixit, MD; Trisha Winchester, PhD; Maeson Latsko, PhD
Additional Resources:
- Quest Diagnostics Polycystic ovary syndrome
- Clinical Focus: Polycystic Ovary Syndrome
- Polycystic Ovary Syndrome (PCOS) Diagnostic Algorithm
- Laboratory Testing in the Differential Diagnosis of PCOS and NCCAH
References See Quest Diagnostics Clinical Education Center
20 min
About Healthier World with Quest Diagnostics
From the publisher's feed
Healthier World with Quest Diagnostics aims to prompt action from insight as we keep you up to date on current clinical and diagnostic topics to transform lives and illuminate a path to better…
health.